4-aminopyridine has been researched along with Ambulation Difficulty in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mobility limitation is a frequent clinical symptom of multiple sclerosis (MS) that poses a therapeutic challenge." | 6.46 | [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis]. ( Hartung, HP; Husseini, L; Kieseier, BC; Leussink, VI, 2010) |
| "Dalfampridine (extended release 4-aminopyridine) is shown in three recent randomised controlled trials to improve walking speed in people with multiple sclerosis; however, the trial literature makes it clear that dalfampridine is effective in only a subset of patients." | 3.80 | Assessing dalfampridine efficacy in the physician's office. ( Malik, O; Nicholas, RS; Raffel, JB, 2014) |
| "Mobility limitation is a frequent clinical symptom of multiple sclerosis (MS) that poses a therapeutic challenge." | 2.46 | [4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis]. ( Hartung, HP; Husseini, L; Kieseier, BC; Leussink, VI, 2010) |
| " The tolerance is good, with mild to moderate, and transient adverse events." | 1.56 | Efficacy and safety of fampridine for walking disability in multiple sclerosis. ( Arpín, EC, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Skov, CD | 1 |
| Sørensen, CB | 1 |
| Thorning, M | 1 |
| Lambertsen, KL | 1 |
| Frich, LH | 1 |
| Jensen, HB | 1 |
| Holsgaard-Larsen, A | 1 |
| Nielsen, HH | 1 |
| Shi, J | 1 |
| Wu, X | 1 |
| Chen, Y | 1 |
| van Munster, CEP | 1 |
| Kaya, L | 1 |
| Lam, KH | 1 |
| Kalkers, NF | 1 |
| Killestein, J | 1 |
| Uitdehaag, BMJ | 1 |
| Arpín, EC | 1 |
| Baird, JF | 1 |
| Sandroff, BM | 1 |
| Motl, RW | 1 |
| Filli, L | 1 |
| Werner, J | 1 |
| Beyer, G | 1 |
| Reuter, K | 1 |
| Petersen, JA | 1 |
| Weller, M | 1 |
| Zörner, B | 1 |
| Linnebank, M | 1 |
| Satchidanand, N | 1 |
| Drake, A | 1 |
| Smerbeck, A | 1 |
| Hojnacki, D | 1 |
| Kolb, C | 1 |
| Patrick, K | 1 |
| Weinstock-Guttman, B | 1 |
| Motl, R | 1 |
| Benedict, RH | 1 |
| Raffel, JB | 1 |
| Malik, O | 1 |
| Nicholas, RS | 1 |
| Limone, BL | 1 |
| Sidovar, MF | 1 |
| Coleman, CI | 1 |
| Hupperts, R | 1 |
| Lycke, J | 1 |
| Short, C | 1 |
| Gasperini, C | 1 |
| McNeill, M | 1 |
| Medori, R | 1 |
| Tofil-Kaluza, A | 1 |
| Hovenden, M | 1 |
| Mehta, LR | 1 |
| Elkins, J | 1 |
| Keune, PM | 1 |
| Cocks, AJ | 1 |
| Young, WR | 1 |
| Burschka, JM | 1 |
| Hansen, S | 1 |
| Hofstadt-van Oy, U | 1 |
| Oschmann, P | 1 |
| Muenssinger, J | 1 |
| Korsen, M | 1 |
| Kunz, R | 1 |
| Schminke, U | 1 |
| Runge, U | 1 |
| Kohlmann, T | 1 |
| Dressel, A | 1 |
| Husseini, L | 1 |
| Leussink, VI | 1 |
| Kieseier, BC | 1 |
| Hartung, HP | 1 |
| Miravalle, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIb, Double-blind, Randomized, Mono-center, Placebo-controlled Study With Crossover Design Characterizing the Effects of Prolonged-release Fampridine Treatment on Ambulatory Function in Patients With Multiple Sclerosis Using Detailed Gait Analysis[NCT01576354] | Phase 2 | 70 participants (Anticipated) | Interventional | 2012-03-31 | Active, not recruiting | ||
| Effects of Dalfampridine on Cognition in Multiple Sclerosis[NCT02006160] | Phase 2/Phase 3 | 61 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Exploratory Study to Assess the Effect of Treatment With Prolonged-Release Fampridine (BIIB041) 10 mg Twice Daily on Walking Ability and Balance in Subjects With Multiple Sclerosis[NCT01597297] | Phase 2 | 132 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Symbol Digit Modalities Test is a measure of cognitive processing speed. The outcome is the total number of correct digit substitutions in 90 seconds, with a possible total range of 0-120. Higher values reflect a better score/outcome than lower scores. (NCT02006160)
Timeframe: Week 0, Week 12
| Intervention | score on a scale (Mean) | |
|---|---|---|
| Week 0 | Week 12 | |
| Control | 35.06 | 38.63 |
| Treatment | 41.18 | 45.05 |
4 reviews available for 4-aminopyridine and Ambulation Difficulty
| Article | Year |
|---|---|
Study on Dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: A meta-analysis.
Topics: 4-Aminopyridine; Disabled Persons; Humans; Immunosuppressive Agents; Mobility Limitation; Multiple S | 2019 |
Therapies for mobility disability in persons with multiple sclerosis.
Topics: 4-Aminopyridine; Exercise Therapy; Humans; Mobility Limitation; Multiple Sclerosis; Potassium Channe | 2018 |
[4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].
Topics: 4-Aminopyridine; Adult; Aged; Clinical Trials, Phase III as Topic; Disability Evaluation; Female; Hu | 2010 |
Guidelines and best practices for appropriate use of dalfampridine in managed care populations.
Topics: 4-Aminopyridine; Benchmarking; Disease Progression; Gait Disorders, Neurologic; Humans; Immunosuppre | 2011 |
5 trials available for 4-aminopyridine and Ambulation Difficulty
| Article | Year |
|---|---|
Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.
Topics: 4-Aminopyridine; Adult; Cross-Over Studies; Double-Blind Method; Female; Gait; Humans; Male; Middle | 2019 |
Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
Topics: 4-Aminopyridine; Adult; Cognitive Dysfunction; Double-Blind Method; Female; Humans; Male; Middle Age | 2020 |
Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Topics: 4-Aminopyridine; Administration, Oral; Adolescent; Adult; Aged; Canada; Delayed-Action Preparations; | 2013 |
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
Topics: 4-Aminopyridine; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Male; Middle Aged | 2016 |
Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
Topics: 4-Aminopyridine; Adult; Biomedical Research; Delayed-Action Preparations; Exercise Test; Female; Hum | 2015 |
5 other studies available for 4-aminopyridine and Ambulation Difficulty
| Article | Year |
|---|---|
Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study.
Topics: 4-Aminopyridine; Disability Evaluation; Follow-Up Studies; Humans; Mobility Limitation; Multiple Scl | 2022 |
Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.
Topics: 4-Aminopyridine; Adult; Clinical Decision-Making; Female; Follow-Up Studies; Humans; Male; Middle Ag | 2020 |
Efficacy and safety of fampridine for walking disability in multiple sclerosis.
Topics: 4-Aminopyridine; Humans; Mobility Limitation; Multiple Sclerosis; Potassium Channel Blockers; Walkin | 2020 |
Assessing dalfampridine efficacy in the physician's office.
Topics: 4-Aminopyridine; Humans; Mobility Limitation; Multiple Sclerosis; Physicians' Offices; Potassium Cha | 2014 |
Dalfampridine effects on cognition, fatigue, and dexterity.
Topics: 4-Aminopyridine; Adult; Cognitive Dysfunction; Depression; Evoked Potentials, Visual; Fatigue; Femal | 2017 |